Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Luye Pharma Switzerland AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is concentrated under 1 distinct examiner and 1 distinct art unit. This indicates that the current prosecution is focused on a specific set of technical claims. This organization characterizes the Biotechnology & Pharmaceuticals portfolio.
MERCIER, MELISSA S is the busiest examiner for this portfolio. This individual is responsible for 1 busiest examiner pending action. Since there is 1 pending office action in the portfolio, MERCIER, MELISSA S is responsible for the active examination. This concentration allows for dialogue between the applicant and the examiner.
The 1 distinct art unit and 1 distinct examiner involved suggest that the applications fall within a specialized category at the patent office. For a practitioner, the outcome of the 1 pending office action will impact the standing of the Luye Pharma Switzerland AG portfolio. The focus remains on the matters before MERCIER, MELISSA S. This examiner manages the 1 busiest examiner pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17794886 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE INGREDIENT ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE | MERCIER, MELISSA S | 1615 | §112 | Final Rejection | 58d overdue | Pending | Mar 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial